Skip to content

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02914704
Enrollment
500
Registered
2016-09-26
Start date
2016-01-31
Completion date
2025-12-31
Last updated
2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Uterine Fibroids

Brief summary

MRI-guided high intensity focused ultrasound (MRI-HIFU) has been proven to be a safe and effective method in treating uterine fibroids and also adenomyosis. However, systematic studies on the effect of this treatment on factors affecting fertility are still lacking. Also quite little is known about body's systemic response to MRI-HIFU. Thus the aim of this study is to obtain more information on the systemic response of the body to the HIFU-treatment when treating non-malignant disease as well as to study the effect of MRI-HIFU on factors affecting fertility. Women with symptomatic uterine fibroids or adenomyosis suitable for MRI-HIFU treatment are recruited to this study. The severity of symptoms will be assessed with UFS-QoL and the same questionnaire will also be used in follow-up 3, 6 and 12 months after treatment. Blood, urine and endometrium samples will be collected pre- and postoperatively and during follow-up 3, 6 and 12 months after the treatment. From these samples detailed analysis of the immunological, inflammatory and hormonal response will be performed. As this is the first study in Finland of treating uterine fibroids and adenomyosis using MRI-HIFU, also a report about the efficacy of the MRI-HIFU in treating the uterine disorders will be published, and a key tool in assessing the treatment outcome would be the UFS-QoL questionnaire. Also new methods for improving patient selection as well as treatment efficacy will be evaluated in this study.

Interventions

DEVICEMRI-HIFU

Treatment of uterine fibroids with MRI-HIFU

Sponsors

Turku University Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI \< 35 * Premenopausal * Uterine size \<20 gw * Willingness to participate to the research * Uterine fibroids with typical symptoms * Maximum of 4 treated fibroids * Dominant fibroid \>2.5cm * \>50% of the fibroid is treatable

Exclusion criteria

* Unspecified pelvic tumours or ovarian masses, PID * Major corrective surgery to uterus (simple myomectomy excluded) * Major uterine anomalies * Unability to calculate the volume of uterine fibroids * Marked uterine calcification * Marked scarring of the lower abdomen * Suspicion of malignancy * Marked general health problem contraindicating MRI * Claustrophobia

Design outcomes

Primary

MeasureTime frame
Technical efficacy of HIFU for treatment of uterine fibroids as assessed by a change in the Symptom Severity Score12 months after treatment

Countries

Finland

Contacts

Primary ContactKirsi M Joronen, PhD
kirsi.joronen@tyks.fi

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026